TP53 and cancer: Indeed, global hypomethylation of LINE‐1 is a well‐established feature in human cancer, and recent evidence has associated it with somatically acquired retrotransposition events that strongly correlate with poor prognosis, TP53 mutation, high copy number alterations, and low immune activity [35, 36].